MMP13

Matrix Metalloproteinase 13 (MMP13), also known as collagenase-3, is a zinc-dependent endopeptidase in the MMP family. It selectively degrades fibrillar collagens (type II, IX, X)—key components of cartilage and bone extracellular matrix (ECM). Its expression is controlled by pro-inflammatory cytokines (IL-1β, TNF-α) and pathways like MAPK and NF-κB, supporting physiological tissue remodeling (e.g., bone growth) but often dysregulated in disease.
Elevated MMP13 activity is a central driver of osteoarthritis (OA), mediating irreversible cartilage breakdown. It also contributes to rheumatoid arthritis (RA) and cancer metastasis (colorectal, breast) via ECM invasion. Broad-spectrum MMP inhibitors (marimastat) had off-target toxicities, so current research focuses on selective MMP13 inhibitors (e.g., CL-82198) for OA, aiming to reduce cartilage loss without systemic side effects, with several candidates in preclinical development.